Carfilzomib 标准品

Description

Carfilzomib is an analog of epoxomicin that functions as a proteasome inhibitor. This drug has been approved for use in humans with multiple myeloma. Carfilzomib binds irreversibly to the 20S proteasome, which exhibits chymotrypsin-like activity and is responsible for degradation of cellular proteins; as a result, concentrations of polyubiquitinated proteins build up, inducing cell cycle arrest at the G2/M phase, apoptosis, and decreased tumor growth.